ArticleInternational dental journal2026
Unveiling Alternative Splicing in HPV-Negative HNSCC: Links to Tumorigenesis and Immune Landscape.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlternative splicing (AS) plays crucial roles in tumorigenesis by regulating cancer development, progression, and patient outcomes. However, the prognostic value of AS in HPV-negative head and neck squamous cell carcinoma (HNSCC), a subtype with distinct clinical features and poor prognosis compared to HPV-positive HNSCC, remains underexplored. This study aimed to develop a robust predictive signature based on AS events in HPV-negative HNSCC.
methodsWe retrieved RNA-sequencing (RNA-seq) data and clinical profiles of the HNSCC cohort from The Cancer Genome Atlas (TCGA) via its data portal. Percentage Spliced In (PSI) values were derived from TCGA SpliceSeq. To identify prognostic AS events in HPV-negative HNSCC, we first performed univariate Cox analysis. Subsequently, we used Least Absolute Shrinkage and Selection Operator (LASSO) regression and stepwise multivariate Cox regression to develop a prognostic signature. The efficacy of this signature in predicting outcomes was assessed using Kaplan-Meier survival curves and receiver operating characteristic (ROC) analyses. Additionally, gene set enrichment analysis (GSEA) was applied to the prognostic signatures. The levels of tumor-infiltrating immune cells were quantified using established deconvolution algorithms (e.g., CIBERSORT, xCell, MCP-counter).
resultsWe identified 42,849 AS events across 388 HPV-negative HNSCC cases, of which 1,062 events were significantly associated with patient prognosis. We developed a prognostic signature based on the 21 most significant AS events, demonstrating high accuracy in predicting survival in HPV-negative HNSCC. This signature emerged as an independent prognostic factor. GSEA and immune microenvironment profiling revealed that the low-risk group exhibited enrichment in immune activation and antigen presentation pathways, in contrast to the high-risk group, which was linked to cell proliferation processes.
conclusionsWe successfully constructed and validated a novel AS-related prognostic signature that enhances personalized survival prediction in patients with HPV-negative HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.